Affinity DataIC50: 1.90nMpH: 4.4Assay Description:The inhibitory activity of compounds was assessed by a fluorescence quench assay of BACE1 activity using commercially available substrate HiLyte Fluo...More data for this Ligand-Target Pair
TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataIC50: 2nMpH: 7.5 T: 2°CAssay Description:The PDE9A2 enzymatic activity assay was run as scintillation proximity assay (SPA), in general according to the protocol of the manufacturer (GE Heal...More data for this Ligand-Target Pair
Affinity DataIC50: 2nMpH: 4.4Assay Description:The inhibitory activity of compounds was assessed by a fluorescence quench assay of BACE1 activity using commercially available substrate HiLyte Fluo...More data for this Ligand-Target Pair
Affinity DataIC50: 2nMpH: 4.4Assay Description:The inhibitory activity of compounds was assessed by a fluorescence quench assay of BACE1 activity using commercially available substrate HiLyte Fluo...More data for this Ligand-Target Pair
Affinity DataIC50: 2nMAssay Description:Assay 1:The assay was performed in the presence of OptiMEM (supernatant collected over 24 h and cleared from cellular debris by centrifugation) conta...More data for this Ligand-Target Pair
Affinity DataIC50: 2.60nMpH: 4.4Assay Description:The inhibitory activity of compounds was assessed by a fluorescence quench assay of BACE1 activity using commercially available substrate HiLyte Fluo...More data for this Ligand-Target Pair
Affinity DataIC50: 2.70nMpH: 4.4Assay Description:The inhibitory activity of compounds was assessed by a fluorescence quench assay of BACE1 activity using commercially available substrate HiLyte Fluo...More data for this Ligand-Target Pair
TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataIC50: 3nMpH: 7.5 T: 2°CAssay Description:The PDE9A2 enzymatic activity assay was run as scintillation proximity assay (SPA), in general according to the protocol of the manufacturer (GE Heal...More data for this Ligand-Target Pair
Affinity DataIC50: 3nMpH: 4.4Assay Description:The inhibitory activity of compounds was assessed by a fluorescence quench assay of BACE1 activity using commercially available substrate HiLyte Fluo...More data for this Ligand-Target Pair
Affinity DataIC50: 3nMpH: 4.4Assay Description:The inhibitory activity of compounds was assessed by a fluorescence quench assay of BACE1 activity using commercially available substrate HiLyte Fluo...More data for this Ligand-Target Pair
Affinity DataIC50: 3nMpH: 4.4Assay Description:The inhibitory activity of compounds was assessed by a fluorescence quench assay of BACE1 activity using commercially available substrate HiLyte Fluo...More data for this Ligand-Target Pair
Affinity DataIC50: 3nMAssay Description:Assay 1:The assay was performed in the presence of OptiMEM (supernatant collected over 24 h and cleared from cellular debris by centrifugation) conta...More data for this Ligand-Target Pair
Affinity DataIC50: 3.40nMpH: 4.4Assay Description:The inhibitory activity of compounds was assessed by a fluorescence quench assay of BACE1 activity using commercially available substrate HiLyte Fluo...More data for this Ligand-Target Pair
TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataIC50: 4nMpH: 7.5 T: 2°CAssay Description:The PDE9A2 enzymatic activity assay was run as scintillation proximity assay (SPA), in general according to the protocol of the manufacturer (GE Heal...More data for this Ligand-Target Pair
Affinity DataIC50: 4nMpH: 4.4Assay Description:The inhibitory activity of compounds was assessed by a fluorescence quench assay of BACE1 activity using commercially available substrate HiLyte Fluo...More data for this Ligand-Target Pair
Affinity DataIC50: 4nMpH: 4.4Assay Description:The inhibitory activity of compounds was assessed by a fluorescence quench assay of BACE1 activity using commercially available substrate HiLyte Fluo...More data for this Ligand-Target Pair
Affinity DataIC50: 4nMAssay Description:Assay 1:The assay was performed in the presence of OptiMEM (supernatant collected over 24 h and cleared from cellular debris by centrifugation) conta...More data for this Ligand-Target Pair
Affinity DataIC50: 4.5nMpH: 4.4Assay Description:The inhibitory activity of compounds was assessed by a fluorescence quench assay of BACE1 activity using commercially available substrate HiLyte Fluo...More data for this Ligand-Target Pair
TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataIC50: 5nMpH: 7.5 T: 2°CAssay Description:The PDE9A2 enzymatic activity assay was run as scintillation proximity assay (SPA), in general according to the protocol of the manufacturer (GE Heal...More data for this Ligand-Target Pair
TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataIC50: 5nMpH: 7.5 T: 2°CAssay Description:The PDE9A2 enzymatic activity assay was run as scintillation proximity assay (SPA), in general according to the protocol of the manufacturer (GE Heal...More data for this Ligand-Target Pair
TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataIC50: 5nMpH: 7.5 T: 2°CAssay Description:The PDE9A2 enzymatic activity assay was run as scintillation proximity assay (SPA), in general according to the protocol of the manufacturer (GE Heal...More data for this Ligand-Target Pair
TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataIC50: 5nMpH: 7.5 T: 2°CAssay Description:The PDE9A2 enzymatic activity assay was run as scintillation proximity assay (SPA), in general according to the protocol of the manufacturer (GE Heal...More data for this Ligand-Target Pair
TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataIC50: 5nMpH: 7.5 T: 2°CAssay Description:The PDE9A2 enzymatic activity assay was run as scintillation proximity assay (SPA), in general according to the protocol of the manufacturer (GE Heal...More data for this Ligand-Target Pair
TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataIC50: 5nMpH: 7.5 T: 2°CAssay Description:The PDE9A2 enzymatic activity assay was run as scintillation proximity assay (SPA), in general according to the protocol of the manufacturer (GE Heal...More data for this Ligand-Target Pair
Affinity DataIC50: 5nMpH: 4.4Assay Description:The inhibitory activity of compounds was assessed by a fluorescence quench assay of BACE1 activity using commercially available substrate HiLyte Fluo...More data for this Ligand-Target Pair
Affinity DataIC50: 5nMpH: 4.4Assay Description:The inhibitory activity of compounds was assessed by a fluorescence quench assay of BACE1 activity using commercially available substrate HiLyte Fluo...More data for this Ligand-Target Pair
Affinity DataIC50: 5nMpH: 4.4Assay Description:The inhibitory activity of compounds was assessed by a fluorescence quench assay of BACE1 activity using commercially available substrate HiLyte Fluo...More data for this Ligand-Target Pair
Affinity DataIC50: 5nMpH: 4.4Assay Description:The inhibitory activity of compounds was assessed by a fluorescence quench assay of BACE1 activity using commercially available substrate HiLyte Fluo...More data for this Ligand-Target Pair
Affinity DataIC50: 5nMpH: 4.4Assay Description:The inhibitory activity of compounds was assessed by a fluorescence quench assay of BACE1 activity using commercially available substrate HiLyte Fluo...More data for this Ligand-Target Pair
Affinity DataIC50: 5nMpH: 4.4Assay Description:The inhibitory activity of compounds was assessed by a fluorescence quench assay of BACE1 activity using commercially available substrate HiLyte Fluo...More data for this Ligand-Target Pair
Affinity DataIC50: 5nMpH: 4.4Assay Description:The inhibitory activity of compounds was assessed by a fluorescence quench assay of BACE1 activity using commercially available substrate HiLyte Fluo...More data for this Ligand-Target Pair
Affinity DataIC50: 5nMpH: 4.4Assay Description:The inhibitory activity of compounds was assessed by a fluorescence quench assay of BACE1 activity using commercially available substrate HiLyte Fluo...More data for this Ligand-Target Pair
Affinity DataIC50: 5nMpH: 4.4Assay Description:The inhibitory activity of compounds was assessed by a fluorescence quench assay of BACE1 activity using commercially available substrate HiLyte Fluo...More data for this Ligand-Target Pair
Affinity DataIC50: 5nMpH: 4.4Assay Description:The inhibitory activity of compounds was assessed by a fluorescence quench assay of BACE1 activity using commercially available substrate HiLyte Fluo...More data for this Ligand-Target Pair
Affinity DataIC50: 5nMAssay Description:Assay 1:The assay was performed in the presence of OptiMEM (supernatant collected over 24 h and cleared from cellular debris by centrifugation) conta...More data for this Ligand-Target Pair
Affinity DataIC50: 5nMAssay Description:Assay 1:The assay was performed in the presence of OptiMEM (supernatant collected over 24 h and cleared from cellular debris by centrifugation) conta...More data for this Ligand-Target Pair
Affinity DataIC50: 5nMAssay Description:Assay 1:The assay was performed in the presence of OptiMEM (supernatant collected over 24 h and cleared from cellular debris by centrifugation) conta...More data for this Ligand-Target Pair
Affinity DataIC50: 5nMAssay Description:Assay 1:The assay was performed in the presence of OptiMEM (supernatant collected over 24 h and cleared from cellular debris by centrifugation) conta...More data for this Ligand-Target Pair
Affinity DataIC50: 5nMAssay Description:Assay 1:The assay was performed in the presence of OptiMEM (supernatant collected over 24 h and cleared from cellular debris by centrifugation) conta...More data for this Ligand-Target Pair
TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataIC50: 6nMpH: 7.5 T: 2°CAssay Description:The PDE9A2 enzymatic activity assay was run as scintillation proximity assay (SPA), in general according to the protocol of the manufacturer (GE Heal...More data for this Ligand-Target Pair
TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataIC50: 6nMpH: 7.5 T: 2°CAssay Description:The PDE9A2 enzymatic activity assay was run as scintillation proximity assay (SPA), in general according to the protocol of the manufacturer (GE Heal...More data for this Ligand-Target Pair
TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataIC50: 6nMpH: 7.5 T: 2°CAssay Description:The PDE9A2 enzymatic activity assay was run as scintillation proximity assay (SPA), in general according to the protocol of the manufacturer (GE Heal...More data for this Ligand-Target Pair
TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataIC50: 6nMpH: 7.5 T: 2°CAssay Description:The PDE9A2 enzymatic activity assay was run as scintillation proximity assay (SPA), in general according to the protocol of the manufacturer (GE Heal...More data for this Ligand-Target Pair
TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataIC50: 6nMpH: 7.5 T: 2°CAssay Description:The PDE9A2 enzymatic activity assay was run as scintillation proximity assay (SPA), in general according to the protocol of the manufacturer (GE Heal...More data for this Ligand-Target Pair
Affinity DataIC50: 6nMpH: 4.4Assay Description:The inhibitory activity of compounds was assessed by a fluorescence quench assay of BACE1 activity using commercially available substrate HiLyte Fluo...More data for this Ligand-Target Pair
Affinity DataIC50: 6nMpH: 4.4Assay Description:The inhibitory activity of compounds was assessed by a fluorescence quench assay of BACE1 activity using commercially available substrate HiLyte Fluo...More data for this Ligand-Target Pair
Affinity DataIC50: 6nMpH: 4.4Assay Description:The inhibitory activity of compounds was assessed by a fluorescence quench assay of BACE1 activity using commercially available substrate HiLyte Fluo...More data for this Ligand-Target Pair
Affinity DataIC50: 6nMpH: 4.4Assay Description:The inhibitory activity of compounds was assessed by a fluorescence quench assay of BACE1 activity using commercially available substrate HiLyte Fluo...More data for this Ligand-Target Pair
Affinity DataIC50: 6nMAssay Description:Inhibition of human BACE1 expressed in HEK293 cellsMore data for this Ligand-Target Pair
Affinity DataIC50: 6nMAssay Description:Inhibition of full-domain of BACE1 expressed in HEK393 cellsMore data for this Ligand-Target Pair